Department of Biomedical Engineering, University of Wisconsin - Madison, Madison, WI, USA.
Methods. 2013 Dec 1;64(2):137-43. doi: 10.1016/j.ymeth.2013.05.027. Epub 2013 Jun 24.
Circulating tumor cells (CTCs) exist in the peripheral blood stream of metastatic cancer patients at rates of approximately 1 CTC per billion background cells. In order to capture and analyze this rare cell population, various techniques exist that range from antibody-based surface marker positive selection to methods that use physical properties of CTCs to negatively exclude background cells from a CTC population. However, methods to capture cells for functional downstream analyses are limited due to inaccessibility of the captured sample or labeling techniques that may be prohibitive to cell function. Here, we present a negative selection method that leverages a Microfluidic Cell Concentrator (MCC) to allow collection and analysis of this rare cell population without needing cell adhesion or other labeling techniques to keep the cells within the chamber. Because the MCC is designed to allow collection and analysis of non-adherent cell populations, multiple staining steps can be applied in parallel to a given CTC population without losing any of the population. The ability of the MCC for patient sample processing of CTCs for enumeration was demonstrated with five patient samples, revealing an average of 0.31 CTCs/mL. The technique was compared to a previously published method - the ELISPOT - that showed similar CTC levels among the five patient samples tested. Because the MCC method does not use positive selection, the method can be applied across a variety of tumor types with no changes to the process.
循环肿瘤细胞(CTCs)存在于转移性癌症患者的外周血液中,其比例约为每十亿背景细胞中有 1 个 CTC。为了捕获和分析这种稀有细胞群体,存在各种技术,从基于抗体的表面标志物阳性选择到利用 CTC 的物理特性将背景细胞从 CTC 群体中排除的方法。然而,由于捕获样本的不可及性或可能对细胞功能产生限制的标记技术,用于捕获细胞进行下游功能分析的方法受到限制。在这里,我们提出了一种阴性选择方法,该方法利用微流控细胞浓缩器(MCC)来允许收集和分析这种稀有细胞群体,而无需细胞粘附或其他标记技术来保持细胞在腔室内。由于 MCC 旨在允许收集和分析非粘附细胞群体,因此可以在给定的 CTC 群体中并行应用多个染色步骤,而不会丢失任何群体。MCC 用于对患者样本进行 CTC 计数的处理能力已通过五个患者样本进行了证明,结果显示平均每个样本中有 0.31 个 CTC/mL。该技术与之前发表的方法-ELISPOT-进行了比较,在测试的五个患者样本中显示出相似的 CTC 水平。由于 MCC 方法不使用阳性选择,因此该方法可以应用于各种肿瘤类型,而无需对该过程进行任何更改。